Please ensure Javascript is enabled for purposes of website accessibility

Why Akebia Therapeutics' Shares Are Soaring 53% Today

By Todd Campbell - Sep 9, 2015 at 2:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Akebia Therapeutics' anemia drug is showing promise in trials, and that could mean it eventually competes against the blockbuster drug Epogen for market share.

Akebia Therapeutics President & CEO John Butler presenting at the American Kidney Fund

What: After reporting positive phase 2 trial results for its anemia drug, shares in Akebia Therapeutics (AKBA -15.40%) jumped by 53% earlier today.

So what: Akebia Therapeutics is developing vadadustat for the treatment of anemia in patients with chronic kidney disease receiving dialysis.

Anemia is common in these patients, and it's frequently treated with Epogen, an erythropoiesis-stimulating agent manufactured by Amgen.

In a 16-week phase 2 trial, Akebia Therapeutics patients that were converted from Epogen to vadadustat didn't see any drop-off in hemoglobin levels. Hemoglobin levels were similar across all three dosing options, including 300 mg daily, 450 mg daily, and 450 mg three times weekly. Importantly, there were no serious safety concerns associated with taking vadadustat.

Now what: Akebia Therapeutics plans to design and launch a phase 3 study soon, and if that study confirms earlier stage findings, then it could result in a needle-moving FDA approval.

That's because Epogen was a multibillion dollar blockbuster drug for Amgen prior to losing patent protection, and even though Epogen faces off against biosimilars overseas, it's still selling at an annualized $2 billion clip.

Vadadustat's oral dosing could give it an important advantage over Epogen, which is injected, but safety is actually the biggest reason why vadadustat could win away market share from Epogen. Epogen has been associated with increasing the risk of cardiac events and with shortening overall survival in certain cancer patients -- risks that haven't been seen in vadadustat's trials to date. 

For that reason, I think that if Akebia Therapeutics skates through its final stage of trials, eases its way through regulators, and nets a favorable prescribing label, then investors could be smart for buying shares of the company now. 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Akebia Therapeutics, Inc. Stock Quote
Akebia Therapeutics, Inc.
AKBA
$0.38 (-15.40%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.